ArticleCancer reports (Hoboken, N.J.)2026

Real-World Outcomes of Acute Myeloid Leukemia Patients Undergoing Treatment With Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2.

Manuel R Espinoza-Gutarra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.